Abstract
Lipoxygenases (LOXs), cytochromes P450 (CYPs) and cyclooxygenases (COXs) catalyze peroxidation of unsaturated fatty acids. In humans they convert arachidonic acid into a variety of eicosanoids, which play a role in all inflammatory responses, cardiovascular and kidney diseases, Alzheimers, cancer and other ailments. Blocking one pathway can prompt the body to switch to the available alternatives. In contrast to CYP and COX, LOX has a non-heme iron co-factor. Several LOXs are produced or stress-induced in the human body. They share the same mechanism, but differ in sequence causing catalysis on the same substrate to be regio- and stereospecific. The action of 15-LOXs could be pro- or anti-inflammatory, and pro- or anticarcinogenic. Depending on the dose, LOXs inhibitors can induce or inhibit other oxygenases. Inhibition of these enzymes presents a great challenge in solving the problem of how to control their action and treat diseases, without causing severe side effects and maintaining/restoring a delicate equilibrium between them. Research on CYPs and COXs is more advanced, while studies of LOXs are lagging behind. This article presents a brief review about LOX structures and inhibition, their involvement in human diseases, and their interplay with other oxidoreductases.
Keywords: Lipoxygenase, fatty acids, inhibition, structure, NSAIDs, regulation of oxygenases, eicosanoids in human diseases
Current Enzyme Inhibition
Title: Lipoxygenases - A Challenging Problem in Enzyme Inhibition and Drug Development
Volume: 3 Issue: 2
Author(s): Ewa Skrzypczak-Jankun, Joanna Chorostowska-Wynimko, Steven H. Selman and Jerzy Jankun
Affiliation:
Keywords: Lipoxygenase, fatty acids, inhibition, structure, NSAIDs, regulation of oxygenases, eicosanoids in human diseases
Abstract: Lipoxygenases (LOXs), cytochromes P450 (CYPs) and cyclooxygenases (COXs) catalyze peroxidation of unsaturated fatty acids. In humans they convert arachidonic acid into a variety of eicosanoids, which play a role in all inflammatory responses, cardiovascular and kidney diseases, Alzheimers, cancer and other ailments. Blocking one pathway can prompt the body to switch to the available alternatives. In contrast to CYP and COX, LOX has a non-heme iron co-factor. Several LOXs are produced or stress-induced in the human body. They share the same mechanism, but differ in sequence causing catalysis on the same substrate to be regio- and stereospecific. The action of 15-LOXs could be pro- or anti-inflammatory, and pro- or anticarcinogenic. Depending on the dose, LOXs inhibitors can induce or inhibit other oxygenases. Inhibition of these enzymes presents a great challenge in solving the problem of how to control their action and treat diseases, without causing severe side effects and maintaining/restoring a delicate equilibrium between them. Research on CYPs and COXs is more advanced, while studies of LOXs are lagging behind. This article presents a brief review about LOX structures and inhibition, their involvement in human diseases, and their interplay with other oxidoreductases.
Export Options
About this article
Cite this article as:
Skrzypczak-Jankun Ewa, Chorostowska-Wynimko Joanna, Selman H. Steven and Jankun Jerzy, Lipoxygenases - A Challenging Problem in Enzyme Inhibition and Drug Development, Current Enzyme Inhibition 2007; 3 (2) . https://dx.doi.org/10.2174/157340807780598350
DOI https://dx.doi.org/10.2174/157340807780598350 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Detrimental Effects of Apolipoprotein E4: Potential Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research MEFV Mutation Carriers and Diseases Other than Familial Mediterranean Fever: Proved and Non-Proved Associations; Putative Biological Advantage
Current Drug Targets - Inflammation & Allergy Linaclotide-a Novel Secretagogue in the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Current Advances in Biochemistry, Medicinal Chemistry and Drug Development Strategies for Age-Related Neurodegenerative Diseases)
Current Topics in Medicinal Chemistry Melatonin in Autism Spectrum Disorders
Current Clinical Pharmacology Exploring Structural and Physicochemical Profiles of Potential GSK-3β Inhibitors Using Structure- and Ligand-Based Modeling Studies
Combinatorial Chemistry & High Throughput Screening Central Nervous System Circuitry and Peripheral Neural Sympathetic Activity Responsible for Essential Hypertension
Current Neurovascular Research Inhibitors of Nitrogen Oxide Species Production in Animal Models of Inflammation and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Cyclodextrins: More than Pharmaceutical Excipients
Mini-Reviews in Medicinal Chemistry Effects of Exercise and Ferulic Acid on Alpha Synuclein and Neuroprotective Heat Shock Protein 70 in An Experimental Model of Parkinsonism Disease
CNS & Neurological Disorders - Drug Targets Metabolic Syndrome the Gynecologist’s Approach
Current Women`s Health Reviews A Comprehensive Literature Review of COPD-Related Fatigue
Current Respiratory Medicine Reviews Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer
Current Drug Targets Targeting SKCa Channels in Cancer: Potential New Therapeutic Approaches
Current Medicinal Chemistry Two-Dimensional QSAR Studies on Arylpiperazines as High-Affinity 5-HT1A Receptor Ligands
Medicinal Chemistry Pharmacological and Biological Therapies for Metabolic Bone Disease in Critical Illness: An Integrative Physiology Approach
Current Drug Therapy Selectivity and Affinity Determinants for Ligand Binding to the Aromatic Amino Acid Hydroxylases
Current Medicinal Chemistry Editorial (Thematic Issue: Neurology and Genetics: How Molecular Biology is Changing the Neurological Thoughts?)
Current Molecular Medicine Identifying Patterns of Psychopathology and Pointing the Way to Effective Interventions
Adolescent Psychiatry Tau in Alzheimer Disease and Related Tauopathies
Current Alzheimer Research